AI Article Synopsis
- In late 2020, the MobyBox, a new ECMO device, was used in Germany to meet the high demand for ECMO therapy during the COVID-19 crisis, particularly for patients with severe ARDS.
- A review of seven patients treated with the MobyBox showed no system failures or adverse events, indicating that it is safe and effective compared to traditional ECMO systems.
- The study suggests the MobyBox may offer better biocompatibility, but further research is necessary to evaluate how its pneumatically driven pump impacts blood components.
Article Abstract
In late 2020, during the second wave of COVID-19 in Germany, we started using the MobyBox, which is a novel fully pneumatically driven ECMO device, on a regular basis to meet the increasing demand for ECMO therapy. In this case series, we performed a retrospective chart review of seven patients with severe COVID-19-related acute respiratory distress syndrome (ARDS) requiring veno-venous (vv)-ECMO support with the MobyBox. During ECMO treatments we have observed no disadvantages in comparison to conventional ECMO systems. There were no system failures or adverse events directly attributable to the MobyBox system. Our data support that providing vv-ECMO with the MobyBox device is safe and feasible. Furthermore, our findings suggest that the MobyBox device might represent an advantage in terms of biocompatibility. Therefore, more data on this issue is needed to better understand how the pneumatically driven pump affects cellular blood components.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MAT.0000000000001685 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First Use of a New Extracorporeal Membrane Oxygenation System in COVID19-Associated Adult Respiratory Distress Syndrome: The MobyBox Device.
ASAIO J
August 2022
From the Department of Anesthesia and Critical Care, ARDS/ECMO-Center, Klinikum Kassel, Kassel, Germany.
Article Synopsis
- In late 2020, the MobyBox, a new ECMO device, was used in Germany to meet the high demand for ECMO therapy during the COVID-19 crisis, particularly for patients with severe ARDS.
- A review of seven patients treated with the MobyBox showed no system failures or adverse events, indicating that it is safe and effective compared to traditional ECMO systems.
- The study suggests the MobyBox may offer better biocompatibility, but further research is necessary to evaluate how its pneumatically driven pump impacts blood components.
Safety and Efficacy of a Novel Pneumatically Driven Extracorporeal Membrane Oxygenation Device.
Ann Thorac Surg
June 2020
Center for Acute Respiratory Failure, Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, New York.
Background: Extracorporeal membrane oxygenation (ECMO) is rapidly becoming a mainstream technology for lung or heart/lung support. Current ECMO devices mostly consist of a power-driven centrifugal pump and a dedicated oxygenator. We studied the safety and efficacy of a novel, fully pneumatically driven ECMO device, which could be used in both venovenous or venoarterial mode in an animal model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!